| Document |
Document Title |
|
JP7153140B2 |
The present disclosure provides 3′ protected nucleotides, including those 3′ protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3′ protected nucleotides are also disclosed, such...
|
|
JP2022110131A |
To provide novel compounds which are STING (Stimulator of Interferon Genes) agonists and are useful for the treatment of disorders that are affected by the modulation of the STING protein.One embodiment of the present invention is a comp...
|
|
JP2022523322A |
To provide a fluorescent GTP analog and its use. The present invention has the following formula: [Chemical 1] (In the formula, X, Y, L, and Ln3+As defined in the specification). [Selection diagram] None
|
|
JP2022059052A |
To provide 5'-cyclo-phosphonate modified nucleotides useful for incorporation into oligomeric compounds, such as RNAi agents.Described are 5'-cyclo-phosphonate modified nucleotides and oligonucleotides such as oligonucleotide interferenc...
|
|
JP2022050518A |
To provide chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and methods for making and using the same.A method for synthesizing chirally controlled oligonucleotides is illustrated in the following s...
|
|
JP7030749B2 |
To provide a chiral reagent or a salt thereof.The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (-NO2), a halogen atom, a cyano group (-CN), a group of f...
|
|
JP7004637B2 |
The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same.
|
|
JP6982358B1 |
An L-glucose derivative represented by the following general formula (1). [Chemical 1][In equation (1), X1Is-SAuR1Indicates a group, X2, X3, X4And X5Are independent of each other, -OR2Group, -NH2Indicates a group or fluorine atom. R1Indi...
|
|
JP6886578B1 |
To provide a compound or a salt thereof selectively accumulated in a tumor tissue, a cancer therapeutic agent using the compound, a photosensitizer, and a fluorescent probe composition. For example, the following compound (IIb) synthesiz...
|
|
JP6867409B2 |
The present invention relates to a process for the purification of methylcobalamin, namely from iron cyanide impurities, comprising contacting a solution comprising methylcobalamin and iron cyanide anions with a strongly basic anion exch...
|
|
JP6802964B2 |
To provide a technique of not stabilizing a double helical structure but selectively stabilizing a quadruple helical structure.Deoxynucleoside in which a methyl group bound to carbon at the 5-position of a pyridine ring of thymidine is s...
|
|
JP2020169206A |
To provide triterpene saponins, methods of synthesis, and uses thereof.The present invention relates to triterpene glycoside saponin-derived adjuvants, synthesis thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-a...
|
|
JP6637492B2 |
The present invention relates to a method for preparing 2′-O-fucosyllactose, the 2′-O-fucosyllactose obtainable by this method and the use thereof. The method comprises reacting the persilylated, protected fucose derivatives of the f...
|
|
JP6621772B2 |
The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.
|
|
JP6608413B2 |
To provide a chiral reagent or a salt thereof.The chiral reagent has following chemical formula (I). In the formula (I), G1 and G2 are independently a hydrogen atom, a nitro group (-NO2), a halogen atom, a cyano group (-CN), a group of f...
|
|
JP6606487B2 |
The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. ...
|
|
JP2019131484A |
To provide a nucleic acid production method using a novel capping agent.There is provided a nucleic acid production method for nucleic acid synthesis on a solid phase. The method comprises: (1) a step of deprotecting a terminal nucleotid...
|
|
JP2019520342A |
The present invention describes a novel conjugate of a drug and part of formula (I) that can bind to a glucose-sensing protein that allows the reversible release of the drug depending on the glucose concentration.
|
|
JP2019509285A |
[Chemical 1] The present invention relates to a method for producing 2'-O-fucosyl lactose and a protected fucosyl donor of formula (I) used in the method. The method comprises reacting a fucose derivative of formula (I) below with a comp...
|
|
JP6487547B2 |
Provided are methods of preparing compounds and pharmaceutical compositions for treating Filoviridae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola vi...
|
|
JP6463750B2 |
This invention is related to nucleic acid chemistry and describes novel 1,2-dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). In addition to these derivatives, 1,2-dithiolan...
|
|
JP6429264B2 |
|
|
JP2018172297A |
To provide a synthesis method having improved yield of sulfur-crosslinked disaccharide compounds.According to the method provided herein, a synthesis starts from 2S,4aR,6S,7R,8R,8aR)-2-phenyl-6-(phenylthio)hexahydropyrano[
3,2-d][1,3]dio...
|
|
JP2018530587A |
The present disclosure relates to cap analogs of formula (I) as defined in claim 1, which can result in high levels of capping efficiency and transcription as well as improved translation efficiency. The present disclosure also relates t...
|
|
JP6371907B2 |
Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typical...
|
|
JP6274570B2 |
|
|
JP6247532B2 |
|
|
JP6230024B2 |
|
|
JP6150440B2 |
A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a...
|
|
JP2017515898A |
Therapeutic agents containing β-l, 6-D-glucan can be combined with the targeting moiety, as well as with methods such as using these conjugates as therapeutic agents to treat a variety of cancers. be able to. Compositions containing a p...
|
|
JP6134710B2 |
The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compo...
|
|
JP2016199561A |
To provide compounds that can effectively penetrate nails, are used for treating ungual and/or periungual fungal infections, and are particularly effective in the topical treatment of onychomycosis and/or cutaneous fungal infections.The ...
|
|
JP5899577B2 |
|
|
JP2015180682A |
To provide processes and intermediates for preparation of compounds having antiviral activity.Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl ...
|
|
JP5779710B2 |
|
|
JP5781026B2 |
The invention provides a conjugate comprising ethylenedicysteine (EC) conjugated to neomycin.
|
|
JP5728086B2 |
|
|
JP5685526B2 |
There is a demand for a convenient production method of an NC type purine nucleoside. The present invention relates to a method of producing a purine nucleoside represented the formula (I') or a salt thereof, which comprising reacting a ...
|
|
JP2014527089A |
The present invention discloses diblock copolymer systems that self-assemble to produce very small structures. These co-polymers consist of one block that contains silicon and another block comprised of an oligosaccharide that are couple...
|
|
JP5597903B2 |
|
|
JP5594722B2 |
|
|
JP5481731B2 |
|
|
JP5448284B2 |
The invention provides a conjugate comprising ethylenedicysteine (EC) conjugated to neomycin.
|
|
JP5372371B2 |
The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under ph...
|
|
JP5366386B2 |
To obtain a composition having excellent nerve cell activation action and nerve stretch promotion action. The composition for nerve cell activation and nerve stretch promotion comprises a compound represented by the formula (1). The comp...
|
|
JP5341956B2 |
A boranophosphate oligomer which is useful as an antisense molecule, etc. and can withstand practical use; and a boranophosphate monomer represented by the following formula (1). The oligomer is obtained by condensing the monomer in the ...
|
|
JP5282258B2 |
To provide a dendrimer capable of being supplied as a medicine. The thioglycoside-type sialic acid-bound dendrimer compound is represented by formula (I) [wherein, E1and E2are each carbon, silicon or germanium, and may be the same or dif...
|
|
JP5227965B2 |
|
|
JP5228002B2 |
|
|
JP2013527128A |
The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions com...
|
